BrainCells is focusing its initial efforts on the treatment of mood disorders and believes its technology has applications in other CNS markets such as cognition, post-traumatic stress disorder and brain repair.
In a short period of time, BrainCells has developed its proprietary neurogenesis platform to the point where it can accurately delineate anti-depressant qualities of new chemical entities with novel mechanisms along with novel combinations of known agents that have not classically been associated with treating various neuropsychiatric disorders.

Positive results from the BCI-952 Phase II study highlight the predictive capability of the BrainCells technology platform. See press release ยป